Ladarixin With Sotorasib in Advanced NSCLC - Phase II
Study record has been combined with NCT05815173. See NCT05815173 for summary.
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
DRUG: Sotorasib|DRUG: Ladarixin
Progression Free Survival (PFS), PFS is the amount of time (months) from initial treatment to disease progression or death from any cause., Up to End of Survival Follow-Up (Up to Month 36)
Percent of Participants who Experience Grade 5 Treatment-Related Adverse Events per CTCAE 5.0, Number of participants whose most severe treatment-related adverse event was rated Grade 5 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, where Grade 5 = death related to adverse event., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Grade 4 Treatment-Related Adverse Events per CTCAE 5.0, Number of participants whose most severe adverse event related to treatment was rated Grade 4 according to CTCAE version 5.0, where Grade 4 = life-threatening consequences; urgent intervention indicated., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Grade 3 Treatment-Related Adverse Events per CTCAE 5.0, Number of participants whose most severe treatment-related adverse event was rated Grade 3 according to CTCAE version 5.0, where Grade 3 = Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living (ADL)., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Grade 2 Treatment-Related Adverse Events per CTCAE 5.0, Number of participants whose most severe treatment-related adverse event was rated Grade 2 according to CTCAE version 5.0, where Grade 2 = Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Grade 1 Treatment-Related Adverse Events per CTCAE 5.0, Number of participants whose most severe treatment-related adverse event was rated Grade 1 according to CTCAE version 5.0, where Grade 1 = Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Complete Response (CR), Percent of participants whose best response is a CR according to RECIST 1.1, where CR = disappearance of all target lesions., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Partial Response (PR), Percent of participants who best response is a PR according to RECIST 1.1, where PR = at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Unconfirmed Complete Response (UCR), Percent of participants who best response is a CR according to RECIST 1.1, but the response has not been confirmed., Up to End of Survival Follow-Up (Up to Month 36)|Percent of Participants who Experience Unconfirmed Partial Response (PR), Percent of participants who best response is a PR according to RECIST 1.1, but the response has not been confirmed., Up to End of Survival Follow-Up (Up to Month 36)|Overall Survival (OS), OS is the amount of time (months) from initial treatment to death due to any cause., Up to End of Survival Follow-Up (Up to Month 36)
Study record has been combined with NCT05815173. See NCT05815173 for summary.